Viridian Therapeutics, Inc. (VRDN) Misses Q3 EPS by 9c

Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q3 EPS of ($1.15), $0.09 worse than the analyst estimate of ($1.06). Revenue for the quarter came in at $86 thousand versus the consensus estimate of $91 thousand.

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• U.S. presses Meta to agree to A.I. reviews as security concerns rise - NYT
• Cerebras Systems posts 94% revenue jump, announces OpenAI deal